Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated Parkinsonian patients - A double blind study

Parkinsonism and Related Disorders

Volumn 3, Issue 4, 1998, Pages 191-193

  Arnold, G ^a,b   Schwarz, J ^a   Macher, C ^a   Oertel, W H ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adverse events; De novo patients; Dopaminergic stimulation; Parkinson's disease

Indexed keywords

ANTIEMETIC AGENT; APOMORPHINE; DOMPERIDONE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; HUMAN; HYPOTENSION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOMITING;

EID: 0031462033     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(97)00032-1     Document Type: Article

References (13)

1. 1. Hughes A.J., Lees A.J., Stern G.M. Challenge test to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991; 41: 1723-1725.
2. 2. Gasser T., Schwarz J., Arnold G., Trenkwalder C., Oertel W.H. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch. Neurol. 1992; 49: 1131-1134.
3. 3. Marty M. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Eur. J. Cancer Clin. Oncol. 1989; 25 (suppl. 1): S41-S45.
4. 4. Campora E., Giudici S., Mertini L., Rubagotti A., Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. Am. J. Clin. Oncol. (CCT) 1994; 17: 522-526.
5. 5. Tyres M.B. Pharmacology and preclinical antiemetic properties of ondansetron. Seminars in Oncology 1992; 19: 1-8.
6. 3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Eur. J. Pharmacol. 1989; 169: 321-324.
7. 7. Gibb W.R.G., Lees A.J. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol. Appl. Neurobiol, 1989; 15: 27-44.
8. 8. Fahn S., Elton R.L., and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D.B., Godstein M., eds. Recent Development in Parkinson's Disease, vol. II. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-163, 292-304.
9. 9. Costall B., Domeney A.M., Naylor R.J., Tyers M.B. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol 1987; 92: 881-894.
10. 10. Zoldan J., Friedberg G., Goldberg-Stern H., Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. The Lancet 1993; 341: 562-563.
11. 11. Algara M., Valls A., Vivancos P., Ganena A. Outpatient total body irradiation for bone marrow transplantation. Bone marrow transplantation 1994; 14: 381-382.
12. 12. Nukariya N., Niitani H., Taguchi T., Furve H., Ota K., Tsukagoshi S., Ariyoshi Y., Ikeda M., Akasaka Y., Ohta J. Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs - dose finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs. Gan To Kagaku Ryoho 1992; 19: 1347-1357.
13. 13. Rudd J.A., Bunce K.T., Naylor R.J. The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology 1996; 36: 91-97.